Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

LDHA (Lactate dehydrogenase A)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

LDH elevation	Melanoma	LDH elevation	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
LDH elevation	Diffuse Large B Cell Lymphoma	LDH elevation	Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
LDHA-L + PD-L1 expression	Melanoma	LDHA-L + PD-L1 expression	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B
LDH elevation	Melanoma	LDH elevation	Melanoma	PD-L1 inhibitor Resistant: B - Late Trials PD-L1 inhibitor Resistant : B	PD-L1 inhibitor Resistant: B - Late Trials PD-L1 inhibitor Resistant : B
BRAF V600 + LDH elevation	Melanoma	BRAF V600 + LDH elevation	Melanoma	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B
TMB-L + LDH elevation	Melanoma	TMB-L + LDH elevation	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B
TMB-H + LDH elevation	Melanoma	TMB-H + LDH elevation	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B
BRAF V600 + LDH elevation + PD-L1 negative	Melanoma	BRAF V600 + LDH elevation + PD-L1 negative	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B	atezolizumab + vemurafenib + cobimetinib Sensitive: B - Late Trials atezolizumab + vemurafenib + cobimetinib Sensitive : B
LDH elevation	Diffuse Large B Cell Lymphoma	LDH elevation	Diffuse Large B Cell Lymphoma	ViPOR Sensitive: C3 – Early Trials ViPOR Sensitive : C3	ViPOR Sensitive: C3 – Early Trials ViPOR Sensitive : C3
LDH elevation	Burkitt Lymphoma	LDH elevation	Burkitt Lymphoma	ViPOR Sensitive: C3 – Early Trials ViPOR Sensitive : C3	ViPOR Sensitive: C3 – Early Trials ViPOR Sensitive : C3
LDH elevation	Gastric Cancer	LDH elevation	Gastric Cancer	ramucirumab Resistant: C3 – Early Trials ramucirumab Resistant : C3	ramucirumab Resistant: C3 – Early Trials ramucirumab Resistant : C3
LDHA elevation	Acute Myelogenous Leukemia	LDHA elevation	Acute Myelogenous Leukemia	azacitidine Sensitive: C3 – Early Trials azacitidine Sensitive : C3	azacitidine Sensitive: C3 – Early Trials azacitidine Sensitive : C3